Clinical trial

Remission With Diet for Ulcerative Colitis Exacerbations: A Single Blinded, International Randomized Controlled Clinical and Translational Trial

Name
0073-22-WOMC
Description
The ReDUCE Trial is a multinational single-blinded randomized controlled trial in mild to moderate flare of Ulcerative colitis (UC) disease patients. The purpose of the study is to validate the clinical efficacy of the UCED (Ulcerative colitis Exclusion Diet) with partial enteral nutrition (PEN) using a novel formula. The investigators anticipate that adding a novel specifically designed dietary intervention in addition to drug will lead to superior remission and mucosal healing via changes in the microbiome.
Trial arms
Trial start
2023-12-01
Estimated PCD
2026-03-01
Trial end
2026-09-01
Status
Recruiting
Treatment
Ulcerative colitis Exclusion Diet
a limited whole food diet (UCED)
Arms:
Ulcerative colitis Exclusion Diet + Partial enteral nutrition
Other names:
UCED
Partial enteral nutrition (PEN)
The diet will be supplemented by 3 glasses a day (750 m"l) of the formula developed for UC using the UCED principles.
Arms:
Ulcerative colitis Exclusion Diet + Partial enteral nutrition
Other names:
UC nutritional formula, Nestle
free diet
oral Budeosnide for 6 weeks + free diet
Arms:
Free diet
Oral Budesonide
Oral Budesonide 9 mg
Arms:
Free diet, Ulcerative colitis Exclusion Diet + Partial enteral nutrition
Size
90
Primary endpoint
Steroid free remission
week 12
Eligibility criteria
Inclusion Criteria: * Informed consent * Established diagnosis of UC with mild to moderate active disease, 5 ≤ SCCAI ≤ 10 * Age: 17-65 years (inclusive) * Extent E1-E3 by the Montreal classification * Active colitis in the rectum or sigmoid colon on sigmoidoscopy * Stable medication use of oral 5ASA for at least 8 weeks, thiopurines, vedolizumabs, Ustekinumab or tofacitinib for at least 12 weeks Exclusion Criteria: * Severe colitis (SCCAI\>10) hospitalization for acute severe colitis (ASC) in the previous 6 months * Use of steroids in the previous 3 months * Patients treated with Anti-TNF currently or in patients who had previously failed or lost response to anti TNF * Vegans (vegetarians may enroll) * Pregnancy * Inability use of budesonide due to severe adverse events * Extraintestinal manifestations such as arthritis, spondyloarthropathy or uveitis * Presence of baseline hypoalbuminemia * Fever \>38°C * Evidence for Clostridioides difficile infection * Renal failure * Hepatitis or PSC (Primary Sclerosing Cholangitis) * Active malignancy (excluding skin BCC).
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'SINGLE', 'maskingDescription': 'The physician', 'whoMasked': ['CARE_PROVIDER']}}, 'enrollmentInfo': {'count': 90, 'type': 'ESTIMATED'}}
Updated at
2024-05-23

1 organization